Peroxiredoxin-1 as a prognostic factor in patients with ovarian cancer

Abstract

Introduction and objective. Peroxiredoxin-1 (PRDX-1) belongs to a family of antioxidant enzymes and has proved to be a versatile molecule regulating cell growth, differentiation and apoptosis. PRDX1-regulated signaling pathways play an important role in the progression and metastasis of human tumours, especially in breast, esophageal and lung cancers. The aim of the study was to evaluate the expression of PRDX-1 in ovarian cancer tissues, and to test the clinical value of PRDX-1 as a prognostic factor in this malignancy. Materials and method. PRDX-1 expression was assessed by automated immunohistochemistry in tumours taken from 55 patients with ovarian cancer during primary surgery. Specimen were formalin-fixed and preserved in paraffin-embedded blocks. The results were correlated with clinicopathological data. Results. A high expression of PRDX-1 was observed in 20% of cases, and was associated with worse compliance to chemotherapy protocol (P<0.002), worse response to chemotherapy (P<0.04), and higher levels of CA 125 after the 1 st line treatment (P<0.004). PRDX-1 positive subjects had a significantly lower 5-year disease-free survival (9.1% vs. 42.6%, P<0.01) and a lower 5-year overall survival (9.1% vs. 56.7%; P<0.002). Multivariate analysis showed that a high expression of PRDX-1 is an independent prognostic factor of poor, overall survival (P<0.002) and a disease-free survival (P<0.01). Conclusion. Results of the study show that PRDX-1 expression in tumour tissues can be another biomarker of prognosis in patients with ovarian cancer.

Assessment of Potential Prognostic Value of Peroxiredoxin 1 in Oral Squamous Cell Carcinoma

“…22 Additionally, Increasing number of studies have found that PRDXs affect the prognosis of patients with various types of tumors, including breast, liver, ovarian, and gastric cancers. [23][24][25][26] PRDX1, PRDX2, and PRDX6 have also been reported to be highly expressed in OSCC. [27][28][29] To date, few studies have investigated the relationship between the PRDX family and metastasis and prognosis of OSCC.…”

Effect of Peroxiredoxin 1 on the biological function of airway epithelial cells and epithelial-mesenchymal transition

“…PRDX1 is a key protein that regulates many physiological processes for the development of various respiratory diseases, cancers, septic shock, and other diseases (Mq et al, 2019;Sieńko et al, 2019). The respiratory epithelium forms an important barrier against inhaled pollutants and microorganisms, and its barrier function is often compromised during inflammatory airway diseases (Olson et al, 2011).…”

The Immune-Related Gene ELF3 is a Novel Biomarker for the Prognosis of Ovarian Cancer

“… 24 PRDX-1 expression in tumor tissue can be a biomarker for the prognosis of patients with OC. 25 Increased expression of TET3 predicts an unfavorable prognosis for OC patients. 26 Low expression of BCL7A is an independent risk factor for poor prognosis in patients with OC.…”